key: cord-0319786-3346icsc
authors: Freuchet, Antoine; Salama, Apolline; Bézie, Séverine; Tesson, Laurent; Rémy, Séverine; Humeau, Romain; Règue, Hadrien; Flippe, Léa; Peterson, Pärt; Vimond, Nadège; Usal, Claire; Ménoret, Séverine; Heslan, Jean-Marie; Duteille, Franck; Blanchard, Frédéric; Giral, Magali; Colonna, Marco; Anegon, Ignacio; Guillonneau, Carole
title: IL-34 deficiency impairs FOXP3+ Treg function and increases susceptibility to autoimmunity
date: 2022-02-05
journal: bioRxiv
DOI: 10.1101/2022.02.04.479184
sha: f042a7de1e2449f3ffb5f393f9bb0d49855de6ec
doc_id: 319786
cord_uid: 3346icsc

Immune homeostasis requires fully functional Tregs with a stable phenotype to control autoimmunity. Although IL-34 is a cytokine first described as mainly involved in monocyte cell survival and differentiation, we recently described its expression by CD8+ Tregs in a rat model of transplantation tolerance and by activated FOXP3+ CD4+ and CD8+ Tregs in human healthy individuals. However, its role in autoimmunity and potential in human diseases remain to be determined. Here we report that the absence of expression of IL-34 in Il34-/- rodents leads to an unstable phenotype, with production of multiple auto-antibodies, exacerbated under inflammatory conditions with increased susceptibility to DSS- and TNBS-colitis in deficient animals. Moreover, we strikingly revealed the inability of Il34-/- CD4+ Tregs to protect Il2rg-/- rats from a wasting disease induced by transfer of pathogenic cells, in contrast to Il34+/+ CD4+ Tregs. We also showed that IL-34 treatment delayed EAE in mice as well as GVHD and human skin allograft rejection in immune humanized immunodeficient NSG mice. Finally, we show that presence of IL-34 in the serum is associated with a longer rejection-free period in kidney transplanted patients. Altogether, our data emphasize on the crucial necessity of IL-34 for immune homeostasis and for CD4+ Tregs suppressive function. Our data also shows the therapeutic potential of IL-34 in human transplantation and auto-immunity.

IL-34 is a homodimeric cytokine binding three distinct receptors or co-receptors, namely CSF-1R (CD115), CD138 (syndecan-1) and PTPz (1, 2) . CSF-1 is another ligand of CD115 but binds with a lower affinity than IL-34, and they both induce survival and differentiation of monocytes toward type 2 "regulatory" macrophages (3, 4) . However, IL-34 and CSF-1 spatio-temporal expressions are mainly distinct and CSF-1 does not bind to CD138 and PTPz (5) . Thus, they have been shown to exert also non-overlapping roles (5) .

We have recently demonstrated that IL-34, but not CSF-1, is significantly overexpressed in antigen-specific CD8 + Tregs from long-term tolerant transplanted rats (treated with CD40Ig, a chimeric molecule blocking the CD40-CD40L pathway) vs. CD8 + Tregs from naive rats (6) (7) (8) .

Further analysis showed that IL-34 expression in human T cells is restricted to, not only activated FOXP3 + CD8 + Tregs, but also to FOXP3 + CD4 + Tregs with about 50% of the FOXP3 + Tregs expressing IL-34 (6, 9) . We also showed that treatment using an AAV encoding IL-34 alone or together with a short sub-optimal dose of rapamycin efficiently delayed or inhibited allograft rejection in vivo in rats through differentiation of tolerogenic macrophages responsible, in turn, for induction of CD4 + and CD8 + Tregs. In this model, the CD4 + and CD8 + Tregs were responsible for the long-term tolerance induction effect of the treatment. In vitro, we showed that IL-34 inhibited both rats and humans effector CD4 + CD25 -T cells proliferation and induced human Foxp3 + CD4 + and CD8 + Tregs expansion (6, 10) . In addition, a suppressive role for IL-34 was also demonstrated by others (11) in rodent liver transplantation models.

While Il34 LacZ/LacZ mice have been studied and no spontaneous autoimmunity or inflammatory diseases were reported (12) , we speculated that it could be due to lack of an inflammatory/autoimmune stimulus. Indeed, in human, increased IL-34 serum levels have been associated to inflammatory diseases (1, 2) , however IL-34 role was not properly described and mostly circumstantial. Thus, the contribution of IL-34 in immune homeostasis, Treg function, as well as its role in autoimmunity and human transplant rejection remains unclear and need to be further addressed. Herein, we generated Il34 -/rats and using both Il34 -/rats and mice, we investigated their phenotype under inflammatory conditions. Using Il34 -/rats, we further analyzed the impact of the absence of expression of IL-34 for CD4 + Tregs suppressive function.

We investigated the potential of IL-34 in human disease to prevent xenogeneic GVHD and human skin allograft rejection in immune humanized immunodeficient NSG mice. Finally, taking advantage of a biocollection, we investigated the correlation between presence of IL-34 in the serum and kidney transplant rejection.

Altogether, our study emphasizes the crucial role of IL-34 for immune homeostasis and for CD4 + Tregs suppressive function and the therapeutic potential of IL-34 in human transplantation and auto-immunity.

To gain further knowledge on the immunoregulatory role of IL-34, we generated an Il34 deficient rat model using CRISPR/Cas9 targeting exon 3 of the rat Il34 gene. The Non-Homologous End Joining (NHEJ) repair mechanism inserted a C base, leading to a STOP codon apparition ( Figure 1A and Supplemental Figure 1A) . The founder animal was mated with an Il34 +/+ animal, the mutation was transmitted to the progeny and homozygous Il34 -/animals were generated as confirmed by heteroduplex mobility assay on an automated microfluidic chip capillary electrophoresis system and sequencing (13, 14) . In absence of available anti-rat IL-34 antibody, we confirmed the knock-out using quantitative RT-PCR and observed a major decrease of Il34 mRNA expression in Il34 -/animals compared to littermates Il34 +/+ animals ( Figure 1B) . Residual mRNA detected was due to mRNA being produced with an immature STOP codon before rapid degradation. The Il34 -/animals looked visually healthy at steady state with normal appearance (Supplemental Figure 1B) , growth (Supplemental Figure 1C ) and bone mass (Supplemental Figure 1D, E) . However, in accordance with the role of IL-34 reported for microglia development and maintenance in the mouse (5), brain analysis showed decreased microglia (CD11b/c + cells) in the hippocampus, but not the cerebellum of the Il34 -/animals ( Figure 1C , D and Supplemental Figure 1F ). Sera analysis showed an increase of ALT and ALT/LDH enzyme levels ratio and a trend for AST and alkaline phosphatase ( Figure   1E ), suggesting mild liver injury. Interestingly, we also observed a strong increase of autoantibodies production against IFN-a1, -a2, -a4, -a7, -a11 and anti-IL-22 in Il34 -/rats ( Figure 1F ) (no evidence for anti-IL-17A/F Ab), increased inflammatory chemokine MIP-2 and decreased eosinophil chemotactic proteins (Eotaxin), as well as regulatory TGF-b3 ( Figure   1G ) (no changes for TGFb1/2, IL-1a/b, -2, -4, -5, -6, -10, -12p70, -13, -17A, G-CSF, GM-CSF, TNFa, IFNg, GROa, MCP-1, -3, MIP-1a, Rantes and IP-10; Supplemental Figure 2A ), altogether suggesting auto-inflammation and an important role for IL-34 in auto-antibody development and cytokine production . Serum levels of immunoglobulin isotypes were normal and antibodies directed against dsDNA were similar to Il34 +/+ rats (Supplemental Figure 2B -C). Histological analysis of organs did not show evidence of tissue lesions or inflammatory infiltrates (Supplemental Figure 2D) . We investigated whether, as compensatory mechanisms that could mitigate the auto-immune symptoms, CSF-1 was upregulated and indeed found significantly higher levels of CSF-1 in the sera of the Il34 -/animals (>6 months old) ( Figure   1H ), suggesting a negative regulation of CSF-1 by IL-34.

Altogether, these results demonstrate a role for IL-34 in rat microglia development and a critical role for regulating auto-antibody development and cytokine production.

In rat, IL-34 deficiency leads to decreased number of CD8 + T cells and an increased susceptibility to colitis.

We then further analyzed the impact of the deficiency on immune cells in mice and rats. While absolute numbers of cells were slightly decreased in thymus, spleen and blood of Il34 -/rats (Figure 2A) , thymic subpopulations, B cell subsets and myeloid cell subsets in spleen were not modified (Supplemental Figures 3A-C) . In contrast, we observed a significant decrease of CD8 + T cells from spleen and blood in Il34 -/rats vs Il34 +/+ rats, but not for CD4 + T cells ( Figure 2B ). In addition, further analysis of lymphocyte function revealed a higher proliferation capacity of CD8 + CD45RC high (effector) T cells (10, 15, 16) , but not of CD4 + CD25effector T cells, in response to a polyclonal stimulation (Figure 2C ), altogether suggesting a role for IL-34 in CD8 + T cell number and proliferative capacity.

The phenotype of FOXP3 + or FOXP3 -CD4 + or CD8 + T cells did not reveal differences in Il34 -/rats vs Il34 +/+ (Supplemental Figures 3D-E) and we observed similar in vitro proliferation capacity for both CD4 + and CD8 + Tregs (Supplemental Figure 3F ).

Gaining insights toward the role of IL-34 in T cell development/function, we next assessed the impact of the global deficiency in an inflammatory environment using the DSS colitis model. For 7 days, 5.5% DSS given in drinking water to Il34 +/+ and Il34 -/rats resulted in an increased severity at all time points in Il34 -/animals compared to Il34 +/+ animals ( Figure 2D) . Moreover, analysis of colon length at day 7 showed that the colon of Il34 -/rats was shorter than Il34 +/+ and control animals ( Figure 2E ). Altogether, our data demonstrate that the lack of IL-34 upon DSS colitis increases its severity.

Since we previously showed that around 50% of FOXP3 + CD4 + and CD8 + Tregs express IL-34 (6), we then tested CD4 + CD25 + (CD4 + Tregs) and CD8 + CD45RC low/-(CD8 + Tregs) Tregs from Il34 -/rats for their capacity to control in vivo wasting disease by i.v transfer of T CD4 + CD45RC high effector cells in Il2rg -/rats ( Figure 3A ) (17) . Strikingly, Il34 -/-CD4 + Tregs were unable to control the development of wasting disease in Il2rg -/animals and death occurred in a similar kinetic than without CD4 + Tregs, in contrast to CD4 + Tregs from Il34 +/+ rats that efficiently controlled wasting disease development (Figure 3B) , demonstrating the critical role of IL-34 in CD4 + Tregs mediated suppressive activity. Histological analysis of the liver and colon from all groups confirmed the cell infiltration and tissue lesions in Il2rg -/animals injected with CD4 + Teff cells without or with CD4 + Tregs from Il34 -/animals, in contrast to animals injected with CD4 + Treg from Il34 +/+ animals ( Figure 3C ). Although we did not observe a protective role of CD8 + Tregs in this model for both Il34 +/+ and Il34 -/-CD8 + Tregs (Figure 3D -E), we observed decreased infiltration in liver and colon in animals injected with CD8 + Tregs from Il34 +/+ animals compared to animals injected with CD4 + Teff cells with or without CD8 + Tregs from Il34 -/animals ( Figure 3E ), suggesting that Il34 -/-CD8 + Tregs were less efficient.

To understand how IL-34 deficiency had modified the function of both CD4 + and CD8 + Tregs in Il34 -/vs. Il34 +/+ rats, we analyzed their transcriptome using DGE-RNAseq. Intriguingly, the transcriptomic landscape of CD4 + and CD8 + Tregs in Il34 -/rats only significantly differed for one gene, Dnaja1, a co-chaperone of heat shock proteins (18) , identically increased in CD4 + and CD8 + Tregs from Il34 -/rats vs CD4 + and CD8 + Tregs from Il34 +/+ rats ( Figure 3F) . Thus, although the role of the increased mRNA expression of Dnaja1 needs to be explored in future work, the major defect in suppressive capacity observed for Tregs from Il34 -/rats is likely not due to a major effect on Tregs direct functions but rather on downstream effects of IL-34 produced by Tregs, mainly through induction of tolerogenic macrophages (4, 6, 9) .

Il34 -/mice are more prone to autoimmunity.

To take advantage of the Il34 -/mouse model (12) , we first analyzed IL-34 expression by Tregs in Il34 +/+ mice ( Figure 4A ) and observed that CD4 + FOXP3 + and CD8 + CD45RC -Tregs express significantly more IL-34 than CD4 + and CD8 + CD45RC high Teff cells ( Figure 4B ), but at lower levels compared to rats and humans (6) . We then assessed susceptibility to autoimmune diseases in Il34 -/mice in models of TNBS induced-colitis and experimental autoimmune encephalomyelitis (EAE) triggered by MOGp35-55 (12) . In the TNBS induced-colitis model, we observed a shorter colon length at day 3 in Il34 -/mice compared to Il34 +/+ and control mice ( Figure 4C) , indicating a more severe inflammation, however we did not observe significant differences in weight loss (Supplemental Figure 4A) . We next investigated the impact of IL-34 deficiency in the EAE model since IL-34 could have a protective role through Treg maintenance and microglia development (19, 12, 6) . Il34 -/mice lost more weight than the controls, but the overall score was not significantly different (Supplemental Figure 4B) , indicating a mild impact of IL-34 deficiency. On the opposite, when we assessed the therapeutic potential of IL-34 therapy in autoimmunity, we observed that the injection of an adenovirus coding for murine IL-34 in association with a sub-optimal dose of rapamycin led to a delayed EAE development compared to the control groups i.e., null adenovirus associated or not with rapamycin ( Figure 4D) .

Thus, altogether, IL-34 deficiency in mice leads to an unstable immune phenotype, with increase susceptible to autoimmunity and inflammation in a specific environment. Moreover, supplementing IL-34 is beneficial in neurodegenerative autoimmune diseases in mice.

Our data so far present a critical role for IL-34 in Treg-mediated suppression and although we previously showed that IL-34 played a role in a transplantation model in rats and mice (9, 6) the question of whether IL-34 has the capacity to inhibit transplant rejection and induce transplant tolerance in an immune response by human cells still remains. Thus, we used transplantation models in immune humanized immunodeficient NSG mice (Figure 5A -B) in which we administered recombinant human IL-34 (rhIL-34) protein using mini-osmotic pumps delivering a constant rate of protein and assessed xenogeneic GVHD or human skin transplant rejection. Administration for 14 days of rhIL-34 protein in association with a sub-optimal dose of rapamycin for 10 days resulted in significant delayed GVHD development with induction of long-term survival in 25% of the recipients ( Figure 5A ) and a significant induction of longterm skin graft tolerance in 50% of the recipients (Figure 5B) , demonstrating the potential of this therapeutic strategy. Analysis of the proportion of hCD45 + cells showed a decrease in animals treated with rapamycin alone vs. control animals and equal inhibition in animals cotreated with rapamycin and rhIL-34 in the acute GHVD model (Supplemental Figure 5A) whereas in the human skin transplantation model the proportion of hCD45 + cells was not modified (Supplemental Figure 5B) . These results can be explained by the inhibition of T effector development and/or function rather a direct inhibition of human lymphocyte proliferation by IL-34. Whether this is due to an increase in Treg function needs further studies.

Pre-transplantation human IL-34 serum levels, but not of CSF-1, is a prognostic marker of a higher rejection-free episode.

We finally assessed the potential use of IL-34 as a biomarker in organ transplantation compared to CSF-1 using serum samples extracted from the DIVAT cohort biocollection (Supplemental IL-34 serum levels were detectable (≥ 37.5 pg/mL) in around 22% of patients in the different groups (Supplemental Figure 6A ) with increased levels in patients who had experienced a rejection compared to stable patients at the post-transplantation period ( Figure 5C ). In contrast, CSF-1 was detectable in most individuals and levels were higher in pre-transplantation compared to post-transplantation as well as in healthy volunteers. CSF-1 levels were also higher in post-transplantation with rejection vs. stable patients ( Figure 5D ). We further analyzed the correlation between IL-34/CSF-1 and the clinical outcome to determine the possibility of using IL-34 or CSF-1 as a prognosis biomarker. We split patients with rejection episodes in two groups based on IL-34 detectability (£ 37.5 pg/mL vs ≥ 37.5 pg/mL) ( Figure 5E and Supplemental Figure 6A ) or CSF-1 mean expression for all patients (£ 2660.94 pg/mL vs ≥ 2660.94 pg/mL) ( Figure 5F ) in serum before transplantation and analyzed the graft survival period before acute rejection episode occurrence. Interestingly and unlike CSF-1, the proportion of patients without rejection episodes in patients with IL-34 levels ≥ 37.5 pg/mL before transplantation was significantly higher than the one of patients with IL-34 below this level.

This statistical correlation was specific when measured before transplantation since IL-34 levels in serum after transplantation did not predict graft outcome (Supplemental Figure 6B -C). Our results thus suggest that IL-34 can act as a prognosis biomarker before transplantation.

Here, we demonstrated IL-34 as a critical actor of Treg-mediated suppression, playing an important role in homeostasis and control of immune responses. IL-34 expression in the T cell lineage seems to be restricted to FOXP3 + CD4 + and CD8 + Tregs (6, 9) acting as a significant suppressor component of their activity. IL-34 is also expressed by other cell subsets such as neurons playing as well a protective role for microglia (20, 21) .

At steady state, the overall phenotype of Il34 -/rats remained similar to the one of Il34 +/+ mice (12, 19) with no evident developmental or pathological signs with the exception of a decrease in microglia. There has not been a thorough description of the distribution and function of other immune cell subsets in Il34 -/mice or on the response to inflammatory/autoimmune stimuli, as described here for Il34 -/animals. The increased expression of auto-antibodies in Il34 -/rats is intriguing suggesting a role for IL-34 the regulation of antibody production. These autoantibodies include anti-IFN-I antibodies that in addition to the role of proinflammatory monocytes/macrophages in the cytokine storm leading to severe acute respiratory distress syndrome and multi-organ pathology observed in SARS-CoV-2 infection could suggest a role for IL-34 in COVID-19 patients (22, 23) .

IL-34 deficiency in rats led to a mild immune phenotype in vivo at resting state, probably due to CSF-1 over-expression that may partially compensate IL-34 deficiency in their common overlapping functions, particularly in monocyte and macrophage differentiation. These results suggest a negative regulation of CSF-1 by IL-34, complementary to the positive regulation of CSF-1 on IL-34 previously described (24) . Despite the fact that CSF-1 could replace activities of IL-34, we still observed some features of a disturbed immune system and differences on the CD8 + T cells lineage distribution pattern. However, upon challenges, we revealed an increased susceptibility to colitis. Even though we did not find any perturbation in myeloid distribution in the gut at steady state (data not shown), one explanation could be that the inflammatory environment could not be counterbalanced by the action of IL-34 on macrophage polarization leading to a greater severity in deficient animals. In the EAE model, the action of IL-34 can be mediated either through the development of microglia (5) or through Treg activity both in the CNS and periphery. As we did not find differences in EAE development when comparing Il34 +/to Il34 -/mice, this would suggest a mild role of IL-34. However, overexpression of IL-34 was beneficial and significantly delayed EAE development showing a therapeutic potential of IL-34 in the initial phases of inflammatory CNS diseases. When we specifically studied the impact of the deficiency in the Treg subsets, we revealed a clear defect in the IL-34 deficient CD4 + Tregs suppressive function where they fail to protect from the wasting disease. This could be due to an insufficient differentiation of M2-like macrophages. This is reminiscent of our observations that IL-34 induces immune tolerance in a model of organ transplantation through M2 macrophages and downstream induction of Treg (9), creating a positive regulatory loop.

Interestingly, transcriptomic analysis of T cells revealed the upregulation only of Dnaja1 in both Il34 -/-CD4 + and CD8 + Tregs compared to Il34 +/+ rats. Dnaja1 encodes for a protein belonging to the heat shock protein 40 (HSP40) acting as a HSP70 co-chaperone. One report has demonstrated a regulatory role of Dnaja1 where it inhibits T cell proliferation and induces IL-10 production by PBMC in rheumatoid arthritis patients (25) . Further work needs to be done in order to comprehend the link between IL-34 and Dnaja1.

IL-34 upregulation has been associated to certain but not all auto-immune diseases. However, the exact contribution of IL-34 in these diseases has not been elucidated since IL-34 upregulation could be a compensatory tolerogenic mechanism, thus a consequence rather than a cause (1, 2) . Moreover, it is important to take into consideration that although IL-34 and CSF-1 share the CSF-1R that could explain results through M2 cells, IL-34 has two other receptors or co-receptors, PTPz and CD138, expressed on other cell types, that could also participate on its final effects (2, 5). IL-34 was shown to delay solid organ graft rejection in animal models and associated with a delayed liver rejection in human (6, 11) . The delay in skin rejection and GVHD in the NSG immune humanized models of the present manuscript are the first ones showing a potent suppressive effect on human immune responses in vivo. As monocytes in NSG mice are only detected in the first few days post-hPBMC injection and rapamycin is needed in this context and in the allotransplantation model in rat (6), we believe, in accordance with previous results (9) that IL-34 first acts on monocytes to differentiate them in M2-like macrophages which will allow to expand Tregs, creating a regulatory environment. (12) . Il2rg -/rats were kindly provided by TRIP Platform (Nantes, France) and have been previously described (26) . The animals were housed in a controlled environment (temperature 21 ± 1 °C, 12-hour light/dark cycle).

and genotyping of Il34 -/-SPD rats. rIL34-sgRNA4

(TGTACTGCAGCTTGCCCCGA) was designed and generated as previously described (27) .

Prepubescent females (4-5 weeks old) were injected with 25 IU pregnant mare serum gonadotropin (Intervet) and followed 48 hours later with 30 IU human chorionic gonadotropin (Centravet, Plancoet, France) before breeding (27) . Fertilized one-cell stage embryos were collected for subsequent microinjection using a previously published procedure (27, 28) . Luciferase Immunoprecipitation Systems (LIPS). LIPS was used for the detection of autoantibodies against cytokines as previously described (29, 30) .

Kit (QIAGEN, Hilden, Germany). Total RNA was isolated from organs (spleen, liver and brain) DSS colitis in rats. DSS (TdB labs, Sweden) was dissolved in drinking water at 5.5% and given to 9-weeks old male rats for 7 days. Weight loss and a disease activity index (DAI=clinical score) were assessed every day. Score is defined as follow: stool consistency: 0 (normal), 2 (loose stool), and 4 (diarrhea); and bleeding: 0 (no blood), 2 (visual pellet bleeding), and 4

(gross bleeding, blood around anus). A day 7, animals were sacrificed and colon length was measured to estimate the inflammation. Adenovirus, coding for murine IL-34 or null, were injected i.v at 4.10 9 IP/100uL/mice two days before the immunization. Rapamycin was i.p injected every day for 15 days at 0.25mg/kg (Rapamune, Pfizer). Animals were monitored daily from day 5 and scored on a 5-point scale as follows: 0, no symptoms; 0.5, tip of tail is limp; 1, loss of total tail tonus; 1.5, loss of total tail tonus and hind leg inhibition; 2, loss of total tail tonus and weakness of hind legs; 2.5, loss of total tail tonus and dragging of hind legs; 3, loss of total tail tonus complete and paralysis of hind legs; 3.5, loss of total tail tonus and paralyzed hind legs are together on one side of the body; 4, loss of total tail tonus, hind leg and partial front leg paralysis; 4.5, loss of total tail tonus, hind leg and front leg paralysis, 5: mouse is found dead due to paralysis. Due to ethical considerations mice were sacrificed when they reached grade 4 for 24 h.

Wasting disease. Il2rg -/-SPD rats aged of 6 weeks were injected via the tail vein with 2.5.10 6

sorted TCRαβ + CD4 + CD45RC high Teff cells from Il34 +/+ rats in association or not with sorted TCRαβ + CD4 + CD25 + CD127 low or TCRαβ + CD4 -CD45RC low/-Tregs from Il34 +/+ or Il34 -/rats at a Teffs:Tregs ratio of 3.5:1 and 2.1:1 respectively. A control with a PBS injection was also performed.

TCRαβ + CD4 + CD25and TCRαβ + CD4 -CD45RC high Teffs, TCRαβ + CD4 + CD25 + CD127 low Tregs, TCRαβ + CD4 -CD45RC low/-T cells from Il34 +/+ and Il34 -/rats were extracted using RNeasy Mini Kit (QIAGEN, Hilden, Germany) and protocol of 3' DGE RNA sequencing was performed as previously described (16) . The differential expression p values were processed with DESeq2 (31).

Immune humanized mouse models. For xenogeneic graft-versus-host-disease (GVHD) model, 1.5x10 7 fresh human PBMC were intravenously injected in 1.5 Gy irradiated NSG mice as previously described (10) . Human PBMC engraftment was monitored in blood and GVHD development was characterized by ≥20% body weight loss. For the skin rejection model, human skins were obtained from healthy donors from abdominoplasty surgery and transplantation was performed as previously described (10). 5.0x10 6 PBMC allogeneic to the graft were i.v injected.

A graft rejection score was established from 0 to 5 based on macroscopic observations: 1: the skin starts to peel off; 2: thick skin; 3: scab; 4: edges start to take off; 5: the skin is entirely Statistics. Mann-Whitney U test was used for qPCR, FACS, positive area in immunohistofluorescence and ELISA analysis. Mantel Cox Log Rank test was used to analyze survival curves. Two-way ANOVA and a Bonferroni posttest were used to compare weight loss and clinical score between groups. Adapted controls were performed together with the test conditions. Animal numbers were determined with ethical committee agreement.

A.F. contributed to data collection, experimentation, analysis and writing of the manuscript. 

The data that support the findings of this study are available from the corresponding author upon reasonable request. 

Immunoregulatory properties of the cytokine IL-34

Interleukin-34, a comprehensive review

Discovery of a cytokine and its receptor by functional screening of the extracellular proteome

IL-34 induces the differentiation of human monocytes into immunosuppressive macrophages. antagonistic effects of GM-CSF and IFNγ

IL-34 and CSF-1, deciphering similarities and differences at steady state and in diseases

IL-34 is a Treg-specific cytokine and mediates transplant tolerance

CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase

Future prospects for CD8 + regulatory T cells in immune tolerance

IL-34 Actions on FOXP3+ Tregs and CD14+ Monocytes Control Human Graft Rejection

Ex Vivo Expanded Human Non-Cytotoxic CD8+CD45RClow/− Tregs Efficiently Delay Skin Graft Rejection and GVHD in Humanized Mice

IL-34 Inhibits Acute Rejection of Rat Liver Transplantation by Inducing Kupffer Cell M2 Polarization

IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia

A Rapid and Cost-Effective Method for Genotyping Genome-Edited Animals: A Heteroduplex Mobility Assay Using Microfluidic Capillary Electrophoresis

Breakdown of Immune Tolerance in AIRE-Deficient Rats Induces a Severe Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy-like Autoimmune Disease

Functional and genetic analysis of two CD8 T cell subsets defined by the level of CD45RC expression in the rat

Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells

OX-22high CD4+ T cells induce wasting disease with multiple organ pathology: prevention by the OX-22low subset

The diversity of the DnaJ/Hsp40 family, the crucial partners for Hsp70 chaperones

Stroma-Derived Interleukin-34 Controls the Development and Maintenance of Langerhans Cells and the Maintenance of Microglia

TGF-β induced by interleukin-34-stimulated microglia regulates microglial proliferation and attenuates oligomeric amyloid β neurotoxicity

Interleukin-34 Selectively Enhances the Neuroprotective Effects of Microglia to Attenuate Oligomeric Amyloid-β Neurotoxicity

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells

DNAJA2, as potential targets of the immune response triggered by bacterial DnaJ in rheumatoid arthritis

Generation of Immunodeficient Rats With Rag1 and Il2rg Gene Deletions and Human Tissue Grafting Models

Homology-directed repair in rodent zygotes using Cas9 and TALEN engineered proteins

Knockout rats generated by embryo microinjection of TALENs

Antibody Profiling by Luciferase Immunoprecipitation Systems (LIPS)

Anti-cytokine autoantibodies suggest pathogenetic links with autoimmune regulator deficiency in humans and mice: Anti-cytokine autoantibodies in mice and humans

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Mann Whitney U test and log-rank tests for survival analysis

Acknowledgments. We thank Séverine Battaglia (Inserm UMR1238, Nantes, France) for performing the Micro-CT analysis and Ms Maire Pihlap for the LIPS analysis. We thank the biological resource center for biobanking of Nantes Hotel-Dieu University hospital (CRB Nantes, F-44093, France -BRIF: BB-0033-00040) for their help in the preparation of the samples. We thank Laure-Hélène Ouisse (ITUN CRTI UMR1064, Nantes, France) for the Ig quantification. This work was partially funded by Labex IGO project (n°ANR-11-LABX-0016-01). Labex IGO is part of the « Investissements d'Avenir » French Government program managed by the ANR. This work was funded by the Agence Nationale de la Recherche ANR-17-CE18-0008, the Fondation du rein "Don de Soi -Don de Vie 2017 FdR-Trans-Forme/FRM" and the Agence de la Biomedecine. This work was also realized in the context of the support provided by the Fondation Progreffe.